Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial

scientific article published in January 2014

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4161/HV.36121
P932PMC publication ID4514070
P698PubMed publication ID25483701
P5875ResearchGate publication ID269284362

P50authorFrank StruyfQ55186651
P2093author name stringGary Dubin
Lan Lin
Jacob Lalezari
Rhoda S Sperling
Mark H Einstein
Archana Chatterjee
HPV-010 Study Group
Marie-Pierre David
Mark M Blatter
Nahida Chakhtoura
Peter Takacs
P2860cites workComparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsQ28255234
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memoryQ34104222
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialQ34580726
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girlsQ34708325
Hepatitis A booster vaccination: is there a need?Q35548831
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized studyQ35886612
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 yearsQ35918834
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upQ36612475
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profileQ37860337
Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trialQ42268011
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responsesQ43782984
Current status of HBV vaccine escape variants--a mathematical model of their epidemiologyQ45103432
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineQ45404942
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialQ45552005
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccQ51865830
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-upQ83428460
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectvaccineQ134808
phase III clinical trialQ42824827
P304page(s)3435-3445
P577publication date2014-01-01
P1433published inHuman Vaccines & ImmunotherapeuticsQ21072749
P1476titleComparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial
P478volume10